Biocon Biologics secures multiple market access agreements for Yesintek
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025. Cigna has added YESINTEK to its commercial formulary beginning on March 21, 2025. UnitedHealthcare has added YESINTEK to several formularies including commercial beginning May 1, 2025; managed Medicaid beginning March 1, 2025; and Medicare beginning June 1, 2025. CVS Health has added YESINTEK beginning July 1, 2025. And finally, Optum Rx has added YESINTEK to its Premium and Select formularies beginning July 1, 2025.
YESINTEK has also been selected on several other formularies, including Navitus, Costco Health Solutions, MedImpact, Priority Health, University of Pittsburgh Medical Center (UPMC), and several other regional health plans. Additionally, YESINTEK has been selected as the exclusive Ustekinumab by Blue Cross Blue Shield of Michigan (BCBSM), Florida Healthcare Plan, and several closed-door health systems.
The Company is also finalizing formulary agreements with other commercial carriers.
YESINTEK is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, increasing patient access to more cost-effective treatment options for use in the treatment of common chronic autoimmune diseases. YESINTEK is available in all the same formulations currently provided by STELERA . The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a day ago
- Time of India
15-year-old pilot shows Crohn's can't ground him
1 2 Ahmedabad: The skies here welcomed a very special visitor on Tuesday afternoon. At just 15, Byron Waller, the first pilot to circumnavigate Australia solo, landed in Ahmedabad, parking his tiny Sling TSi aircraft at the Sardar Vallabhbhai Patel International (SVPI) airport. Byron, a Crohn's disease patient since childhood, is on a record-setting flight around the globe. His journey is not only about breaking barriers in aviation. He comes with a message of resilience and courage, showing that hope can take flight even in the face of illness. For Byron, the cockpit is more than just an adventure; it is liberation. Diagnosed with Crohn's disease, a type of inflammatory bowel disease, he spent years in and out of hospital wards. "I spent a lot of time in the hospital. Watching planes fly by from my window became the highlight of my day. It gave me a sense of adventure, even while being confined to a hospital room," he said. That longing for the skies soon hardened into determination. In 2024, at only 14, Byron embarked on a 19-day charity flight across Australia, covering over 11,000km to raise awareness for Crohn's disease, and to inspire children battling health challenges. Aptly titled From Patient to Pilot, his mission proved that illness could not clip his wings. This year, he has taken that dream further. Setting off from Port Hedland, Australia, on Aug 12, Byron has already flown across Christmas Island, Singapore, and Colombo before touching down in Ahmedabad. Each landing is more than a stopover; it is a connection. "Don't let anything hold you back, your dreams are worth fighting for," he told young Indians on Tuesday. "If we stay united, determined, and positive, anything is possible." You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad | Gold Rates Today in Ahmedabad | Silver Rates Today in Ahmedabad But the journey has not been without its challenges. One of the toughest stretches so far, Byron says, was the Pacific leg. "Flying over the vast ocean was both awe-inspiring and daunting. On Aug 15, we navigated through storm systems that even diverted jetliners," he recalled. "What kept me steady was meticulous preparation, mental resilience, and the guiding hand of my instructor, Paul Denness." Byron didn't grow up like any other teenager his age. "Having spent many years of my life confined to hospitals and unable to do the things other children my age were doing, it has been really motivating for me to be part of the typical teenage routine now. I have a great support system, including my family, friends, and mentors, who keep me grounded and motivated," he said. As he charts his way further across the globe, Byron insists this journey is only the beginning. "After completing this world flight, I want to keep pushing my limits in aviation and continue spreading my message of hope, especially for kids living with health challenges. I'll also return to school for Grade 11, balancing studies with my passion," he said. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
News18
2 days ago
- News18
Inflammatory Bowel Disease In India: Why Early Diagnosis And Awareness Matter More Than Ever
IBD in India is underdiagnosed or misdiagnosed, and is often mistaken for common conditions such as infections or irritable bowel syndrome Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic condition that triggers inflammation in the digestive system. It affects a person both physically and mentally. Overseas, the illness is well studied and effectively treated through collective awareness, early diagnosis, and access to medical care. In India, however, the disease is often disregarded. Still considered rare, it is now being reported more frequently, particularly in urban centres. From a mere 0.1% in 2006 to more than 5% by 2022, the incidence rate has risen sharply. More than a doctor's statistic, this is an alarm bell. The increase has been linked to the westernisation of eating habits, stress, sedentary lifestyles, and unrestricted antibiotic use, all of which can disrupt gut health and contribute to the disease. Despite this surge, IBD in India is underdiagnosed or misdiagnosed, and is often mistaken for common conditions such as infections or irritable bowel syndrome. Dr Hardik Parikh, Gastroenterologist shares all you need to know: The absence of early diagnosis exacerbates symptoms that could otherwise be managed or prevented. Gut health is not openly discussed in India due to stigma and low awareness, but rising cases and lifestyle-related risks make it more important than ever to diagnose IBD early and raise awareness to improve outcomes and provide timely treatment. Significance of Early Diagnosis Common signs of IBD include chronic diarrhoea, crampy abdominal pain, unexplained weight loss, fatigue, and blood in the stool. However, these symptoms are often misinterpreted as routine gastrointestinal ailments in India, where self-treatment is widespread. This causes delays in referrals to specialists. Timely diagnosis can make a significant difference. Once patients are aware of their condition, they can seek treatment that helps manage inflammation, relieve symptoms, and avoid complications in the long run. Without proper and timely diagnosis, IBD can lead to serious health challenges such as intestinal damage, anaemia, and malnutrition. Early diagnosis also improves the mental and emotional well-being of patients. Unexplained pain, repeated hospital visits, and uncertainty about the illness often trigger depression and anxiety. Awareness of the condition and its management empowers patients to lead more comfortable, fulfilling lives. Countering Current Disease Ignorance In India, IBD remains an unfamiliar ailment. This lack of awareness fuels stigma, delays treatment, and causes social isolation. Awareness campaigns can play a crucial role in changing this. Events like World IBD Day on 19 May help inform the public about the disease, its symptoms, management, and the importance of timely treatment. Awareness also encourages patients to seek medical assistance. Digestive and bowel issues are still not openly discussed in Indian families, but breaking this silence is essential for early treatment and counselling. Awareness initiatives can also influence health policy, encouraging the government to invest in better facilities, diagnostic equipment, and specialist training. The psychological impact of IBD is also frequently overlooked. Many patients struggle with shame, loss of employment or school days, and social withdrawal. Anxiety and depression are common. Open communication and awareness can significantly reduce this burden. Making IBD Visible IBD is no longer a rare disease in India. It is emerging as a community health issue due to lifestyle and dietary triggers. Yet, there is hope: effective management is possible with early detection and greater awareness. Doctors, public health professionals, the media, and communities must work together to raise awareness, reduce stigma, and improve access to timely care. With early warning signs recognised, much of the pain and disruption caused by IBD can be prevented, allowing patients to seek care on time. Though IBD remains a silent disorder, its impact is real. With timely medical intervention, greater awareness, and social understanding, people living with IBD can lead active and healthy lives. view comments First Published: August 19, 2025, 17:01 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy. Loading comments...
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Fitch warns US tariffs could hit Indian pharma and oil firms' earnings
Global rating agency Fitch on Friday said Indian companies in sectors such as pharmaceuticals may be hit by further US tariff announcements, adding that the risk of second-order effects from existing tariffs is also rising. India-based corporations generally have low direct exposure to US tariffs, but sectors currently unaffected, including pharmaceuticals, could be hit if additional duties are imposed. A US-India trade deal, if secured, would reduce these risks, the agency noted. The United States imposed 25 per cent 'reciprocal' tariffs on India with effect from August 7, 2025, and an additional 25 per cent levy on its oil imports from Russia, effective August 27, 2025. A US delegation was slated to visit India for trade negotiations next week, but the plans have been postponed without any announcement of new dates. The US is a key export destination for Indian pharmaceutical companies. Biosimilars-focused Biocon Biologics derives around 40 per cent of its sales from the US, mostly from production sites in India and Malaysia. Significant tariffs on pharmaceutical products are not yet factored into the rating base case and could pose downside risks to its operating performance, Fitch said. The competitive industry landscape could limit Biocon's ability to pass on higher costs despite the non-discretionary demand for its products. On tariffs for Russian oil imports, Fitch said Russian crude accounts for about 30–40 per cent of crude imports for Indian oil marketing companies (OMCs), with its discounted price supporting their earnings before interest, tax, depreciation and amortisation (Ebitda) and profitability. The agency's base case assumes the Indian government will not limit OMC purchases of Russian crude. If curtailed, it would hurt Ebitda, but the impact would be around 10 per cent in the case of a full halt. Support-driven OMCs' issuer default ratings, such as those of Bharat Petroleum, Indian Oil and Hindustan Petroleum, would remain unaffected under this scenario. However, HPCL-Mittal Energy has a lower rating buffer and its credit profile could be more vulnerable to a sharp deterioration in earnings that would hinder its deleveraging prospects, Fitch added. India's direct automotive exports to the US, including parts, are limited. The US accounts for close to 20 per cent of sales for auto supplier Samvardhana Motherson International, but mostly from production bases in the US or in Mexico that benefit from tariff exemptions under the United States-Mexico-Canada Agreement. Nonetheless, Fitch revised the outlook on SAMIL to Stable from Positive in May 2025, reflecting its expectation that a weakened global auto sector outlook amid tariff-related uncertainty would limit further improvement in the company's financial leverage.
